TY - JOUR
T1 - Exposure toThioguanine During 117 Pregnancies inWomen With Inflammatory Bowel Disease
AU - Crouwel, Femke
AU - Simsek, Melek
AU - de Boer, Marjon A.
AU - Mulder, Chris J.J.
AU - van Andel, Emma M.
AU - Creemers, Rob H.
AU - van Asseldonk, Dirk P.
AU - van Bodegraven, Ad A.
AU - Horjus, Carmen S.
AU - Visschedijk, Marijn C.
AU - Weusthuis, Angelique L.M.
AU - Seinen, Margien L.
AU - Jharap, Bindia
AU - van Schaik, Fiona D.M.
AU - Ahmad, Ishfaq
AU - Boekema, Paul J.
AU - Tack, Greetje J.
AU - Wormmeester, Louktje
AU - Lutgens, Maurice W.M.D.
AU - van Boeckel, Petra G.A.
AU - Gilissen, Lennard P.L.
AU - Kerkhof, Marjon
AU - Russel, Maurice G.V.M.
AU - Hoentjen, Frank
AU - Bartelink, Maartje E.
AU - Kuijvenhoven, Johan P.
AU - Maljaars, Jeroen W.J.
AU - van Dop, Willemijn A.
AU - Wonders, Janneke
AU - van der Voorn, Michael M.P.J.A.
AU - Buiter, Hans J.C.
AU - de Boer, Nanne K.
N1 - Funding Information:
We would like to thank Hans Lubbinge from Tjongerschans Ziekenhuis for the inclusion of patients.
Publisher Copyright:
© The Author(s) 2022.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Background: Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth. Methods: In this multicentre case series, IBD patients treated with thioguanine during pregnancy were included. Data regarding disease and medication history, pregnancy course, obstetric complications, and neonatal outcomes were collected. Results: Data on 117 thioguanine-exposed pregnancies in 99 women were collected. Most [78%] had Crohn’s disease and the mean age at delivery was 31 years. In 18 pregnancies [15%], IBD flared. Obstetric and infectious complications were seen in 15% [n = 17] and 7% [n = 8] of pregnancies, respectively. Ten pregnancies [8.5%]and one in an induced abortion due to trisomy 21. In total, 109 neonates were born from 101 singleton pregnancies and four twin pregnancies. One child was born with a congenital abnormality [cleft palate]. In the singleton pregnancies, 10 children were born prematurely and 10 were born small for gestational age. Screening for myelosuppresion was performed in 16 neonates [14.7%]; two had anaemia in umbilical cord blood. All outcomes were comparable to either the general Dutch population or to data from three Dutch cohort studies on the use of conventional thiopurines in pregnant IBD patients. Conclusion: In this large case series, the use of thioguanine during pregnancy is not associated in excess with adverse maternal or neonatal outcomes.
AB - Background: Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth. Methods: In this multicentre case series, IBD patients treated with thioguanine during pregnancy were included. Data regarding disease and medication history, pregnancy course, obstetric complications, and neonatal outcomes were collected. Results: Data on 117 thioguanine-exposed pregnancies in 99 women were collected. Most [78%] had Crohn’s disease and the mean age at delivery was 31 years. In 18 pregnancies [15%], IBD flared. Obstetric and infectious complications were seen in 15% [n = 17] and 7% [n = 8] of pregnancies, respectively. Ten pregnancies [8.5%]and one in an induced abortion due to trisomy 21. In total, 109 neonates were born from 101 singleton pregnancies and four twin pregnancies. One child was born with a congenital abnormality [cleft palate]. In the singleton pregnancies, 10 children were born prematurely and 10 were born small for gestational age. Screening for myelosuppresion was performed in 16 neonates [14.7%]; two had anaemia in umbilical cord blood. All outcomes were comparable to either the general Dutch population or to data from three Dutch cohort studies on the use of conventional thiopurines in pregnant IBD patients. Conclusion: In this large case series, the use of thioguanine during pregnancy is not associated in excess with adverse maternal or neonatal outcomes.
KW - Inflammatory bowel disease
KW - pregnancy
KW - thioguanine
U2 - 10.1093/ecco-jcc/jjac183
DO - 10.1093/ecco-jcc/jjac183
M3 - Article
C2 - 36521000
AN - SCOPUS:85159548860
SN - 1873-9946
VL - 17
SP - 738
EP - 745
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 5
ER -